Literature DB >> 15541473

Relation between bone marrow angiogenesis and serum levels of angiogenin in patients with myelodysplastic syndromes.

Michael G Alexandrakis1, Freda H Passam, Constantina A Pappa, Katerina Sfiridaki, George Tsirakis, John Damilakis, Efstathios N Stathopoulos, Despina S Kyriakou.   

Abstract

Angiogenesis is implicated in the progression of myelodysplastic syndromes (MDS). Bone marrow microvascular density (MVD), serum angiogenin (ANG) and interleukin 6 (IL-6) were measured in 67 patients with untreated MDS. MVD, ANG and IL-6 were significantly higher in the patient group as a whole when compared to controls (P < 0.01). MVD and ANG were significantly higher in subtypes with a high-risk for leukemic transformation (RAEB, RAEB-t and CMML) than in low-risk subtypes (RA and RARS) (P < 0.01). In the MDS group, a positive correlation was found between ANG and IL-6 (P < 0.001) and also between MVD and IL-6 (P < 0.05). Using multivariate analysis, only IL-6 displayed independent prognostic value and was inversely related to MDS survival.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15541473     DOI: 10.1016/j.leukres.2004.05.002

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  12 in total

1.  Mechanism and Function of Angiogenin in Hematopoietic Malignancy.

Authors:  Kevin A Goncalves; Guo-Fu Hu
Journal:  Zhongguo Sheng Wu Hua Xue Yu Fen Zi Sheng Wu Xue Bao       Date:  2015-12-23

2.  Angiogenesis and survival in patients with myelodysplastic syndrome.

Authors:  Aleksandar Savic; Vesna Cemerikic-Martinovic; Sinisa Dovat; Nebojsa Rajic; Ivana Urosevic; Borivoj Sekulic; Vanja Kvrgic; Stevan Popovic
Journal:  Pathol Oncol Res       Date:  2012-01-24       Impact factor: 3.201

3.  Tumor microenvironment and clonal monocytes from chronic myelomonocytic leukemia induce a procoagulant climate.

Authors:  Johanna Zannoni; Natacha Mauz; Landry Seyve; Mathieu Meunier; Karin Pernet-Gallay; Julie Brault; Claire Jouzier; David Laurin; Mylène Pezet; Martine Pernollet; Jean-Yves Cahn; Fabrice Cognasse; Benoît Polack; Sophie Park
Journal:  Blood Adv       Date:  2019-06-25

Review 4.  Endothelial progenitor cells in hematologic malignancies.

Authors:  Ugo Testa; Ernestina Saulle; Germana Castelli; Elvira Pelosi
Journal:  Stem Cell Investig       Date:  2016-07-01

5.  Antiangiogenic therapy in myelodysplastic syndromes: is there a role?

Authors:  Stephen T Oh; Jason Gotlib
Journal:  Curr Hematol Malig Rep       Date:  2008-01       Impact factor: 3.952

Review 6.  Chronic myelomonocytic leukemia: Forefront of the field in 2015.

Authors:  Christopher B Benton; Aziz Nazha; Naveen Pemmaraju; Guillermo Garcia-Manero
Journal:  Crit Rev Oncol Hematol       Date:  2015-03-14       Impact factor: 6.312

7.  High bone marrow angiopoietin-1 expression is an independent poor prognostic factor for survival in patients with myelodysplastic syndromes.

Authors:  C-L Cheng; H-A Hou; J-Y Jhuang; C-W Lin; C-Y Chen; J-L Tang; W-C Chou; M-H Tseng; M Yao; S-Y Huang; B-S Ko; S-C Hsu; S-J Wu; W Tsay; Y-C Chen; H-F Tien
Journal:  Br J Cancer       Date:  2011-08-30       Impact factor: 7.640

Review 8.  The Potential of Angiogenin as a Serum Biomarker for Diseases: Systematic Review and Meta-Analysis.

Authors:  Dongdong Yu; Yikai Cai; Wei Zhou; Jinghao Sheng; Zhengping Xu
Journal:  Dis Markers       Date:  2018-03-15       Impact factor: 3.434

9.  Alteration in the Cytokine Secretion of Bone Marrow Stromal Cells from Patients with Chronic Myelomonocytic Leukemia Contribute to Impaired Hematopoietic Supportive Activity.

Authors:  Hui Shi; Yingshao Wang; Rong Li; Wen Xing; Feng-Chun Yang; Jie Bai; Yuan Zhou
Journal:  Stem Cells Int       Date:  2018-07-10       Impact factor: 5.443

10.  Alteration in endoglin-related angiogenesis in refractory cytopenia with multilineage dysplasia.

Authors:  Mónica del Rey; Miguel Pericacho; Soraya Velasco; Eva Lumbreras; José Miguel López-Novoa; Jesús María Hernández-Rivas; Alicia Rodríguez-Barbero
Journal:  PLoS One       Date:  2013-01-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.